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CcbJ is an S-Adenosylmethionine (SAM) dependent methyltransferase from S. caelestis which catalyzes the final step in the biosynthesis of the antibiotic celesticetin. S. caelestis has exhibited the ability to synthesize different derivatives of celesticetin depending on the presence of different salicylic acid derivatives in the growth medium.
[2] In order to understand how this organism is able to manage this, we have isolated, overexpressed, and purified the individual components of this pathway, including CcbJ [3] .
The crystal structure of free CcbJ was determined by Multiwavelength Anomalous Dispersion and that of the CcbJ-SAM complex was determined by molecular replacement (using the free structure as the search model). In both structures CcbJ crystallized in the C222 1 space group with unit cell lengths of a = 168.02, b = 244.55, and c = 117.85. In both crystals, the asymmetric unit contained six monomers arranged as a dimer of trimers.
CcbJ possesses the class I SAM-dependent methyltransferase fold [4], [5] ; modifications to the core fold include insertion of a fourstranded β-sheet, which serves as an active site cover, between αE and β5 and a short 3 10 helix between β4 and αD, which forms part of the SAM binding cleft. There is also an extension to the N-terminus. These insertions match the general pattern seen in other small-molecule methyltransferases. Overall, CcbJ appears to be most similar to glycine N-methyltransferase (GNMT) which also has a similar active site cover and a 3 10 helix in the SAM binding cleft. Aside from a similar overall shape, the active site of CcbJ is quite different from that of GNMT, having a much larger number of aromatic residues.
One of the most characteristic features of CcbJ is the great degree of flexibility exhibited by the residues in the N-terminal extension preceding αZ. In the free CcbJ structure, these residues were completely disordered in one of the six chains and none of the residues preceding Tyr-17 were visible. In the CcbJ-SAM complex, however, the entire extension was visible in all six chains. The newly ordered residues form an α-helix which passes between the active site cover and αB and forms part of the SAM binding site. Following this helix, the extension passes over part of the active site opening before entering helix αZ. The loop between these two helices contains several proline and glycine residues and is likely to be natively unstructured. This would probably allow it to adopt several different conformations which might allow it to accommodate the several different substrates observed in vivo [2] . [ ellipsoids are displayed at the 50% probability level. has been used as a tool to help understand specific binding interactions of inhibitors to various MMPs. Large conformational changes have been noted when comparing the structures of the active MMP-3 catalytic domain and the one inhibited by a hydroxamic acid inhibitor. Both soaking and co-crystallization methods were used to generate the MMP-3/ inhibitor complex crystals for data collection. The same inhibitor has also been co-crystallized with MMP-1 and MMP-13. Comparisons of the structures of three inhibited enzymes, MMP-1, 3, and 13 show that MMP-3 and 13 are extremely similar. There are major differences in the binding pockets, especially in the S1' pocket between MMP-1 and MMP-3/13. These structural studies have helped design more selective inhibitors that can be used as therapeutic agents with improved safety profile.
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